New England Journal of Medicine最新文献

{"title":"HFpEF Explained - Living with HFpEF.","authors":"Sadiya S Khan, Donald Lloyd-Jones, Neha J Pagidipati, Sanjiv J Shah, Caitlan Pawlowski, Lori Hogan, Janice Williams, Jane Leopold","doi":"10.1056/NEJMp2516849","DOIUrl":"https://doi.org/10.1056/NEJMp2516849","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"394 18","pages":"e35"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Daraxonrasib in Previously Treated Advanced <i>RAS</i>-Mutated Pancreatic Cancer.","authors":"Brian M Wolpin, Wungki Park, Ignacio Garrido-Laguna, Alexander Spira, Alexander Starodub, David Sommerhalder, Salman R Punekar, Minal Barve, Meredith Pelster, Benjamin Herzberg, Nilofer S Azad, Joel Randolph Hecht, Sai Hong Ignatius Ou, Tong Lin, Sumit Kar, Lin Tao, Rashmi Vora, Aparna Hegde, Kyaw Aung, David S Hong","doi":"10.1056/NEJMoa2505783","DOIUrl":"https://doi.org/10.1056/NEJMoa2505783","url":null,"abstract":"<p><strong>Background: </strong>Current therapies for patients with pancreatic ductal adenocarcinoma (PDAC) provide modest benefit. Activating <i>RAS</i> mutations occur in more than 90% of PDAC tumors. Daraxonrasib (RMC-6236) is an oral RAS(ON) multiselective inhibitor that targets guanosine triphosphate-bound mutant and wild-type RAS.</p><p><strong>Methods: </strong>In this phase 1-2 study, we evaluated daraxonrasib in patients with advanced solid tumors with activating <i>RAS</i> mutations. Patients received 10 to 400 mg of daraxonrasib orally once daily; 300 mg was selected as the phase 3 dose. The primary end point was safety. Pharmacokinetics and antitumor activity were secondary end points. This report focuses on the 168 study patients with previously treated <i>RAS</i>-mutated PDAC.</p><p><strong>Results: </strong>Among the 168 patients with PDAC who received daraxonrasib at a dose of 300 mg or less, treatment-related adverse events of any grade were reported in 96%; such events of grade 3 or higher were reported in 30%. Treatment-related adverse events that occurred in at least 10% of the patients included rash, diarrhea, nausea, stomatitis or mucositis, vomiting, and fatigue. In a subgroup of 26 patients with <i>RAS</i> G12 mutations who were treated with second-line daraxonrasib at a dose of 300 mg, an objective response to therapy was reported in 35% (95% confidence interval [CI], 17 to 56). The median duration of response was 8.2 months (95% CI, 3.8 to not evaluable), with median values of 8.5 months for progression-free survival and 13.1 months for overall survival. Among the 38 patients with <i>RAS</i> G12, G13, or Q61 mutations, 29% (95% CI, 15 to 46) had an objective response. The median duration of response was 8.2 months (95% CI, 3.8 to 8.8), with median values of 8.1 months for progression-free survival and 15.6 months for overall survival.</p><p><strong>Conclusions: </strong>Daraxonrasib was associated with treatment-related adverse events of grade 3 or higher in one third of patients with previously treated <i>RAS</i>-mutated PDAC; antitumor activity was also reported. (Funded by Revolution Medicines; RMC-6236-001 ClinicalTrials.gov number, NCT05379985.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"394 18","pages":"1790-1802"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evidence-Based Approach to Covid-19 Vaccination.","authors":"Ghady Haidar, Katrina E Hauschildt, Marian G Michaels","doi":"10.1056/NEJMc2507760","DOIUrl":"10.1056/NEJMc2507760","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"e37"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evidence-Based Approach to Covid-19 Vaccination.","authors":"Dimitri Drekonja","doi":"10.1056/NEJMc2507760","DOIUrl":"https://doi.org/10.1056/NEJMc2507760","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"394 18","pages":"e37"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral Amyloid Angiopathy.","authors":"Steven M Greenberg","doi":"10.1056/NEJMra2411298","DOIUrl":"https://doi.org/10.1056/NEJMra2411298","url":null,"abstract":"<p><p>Cerebral amyloid angiopathy is a major cause of hemorrhagic stroke, a frequent contributor to age-related cognitive impairment, and a key component in adverse responses to beta-amyloid (Aβ) immunotherapy. Defined by pathological deposition of Aβ in the small blood vessels of the brain, cerebral amyloid angiopathy is most often diagnosed on the basis of magnetic resonance imaging studies showing multiple hemorrhages or leptomeningeal blood products within or overlying the cerebral cortex. The disorder typically manifests as hemorrhagic stroke or as a contributing factor to cognitive decline and, less commonly, with transient focal neurologic symptoms or a cerebral inflammatory autoimmune syndrome. The high risk of recurrent hemorrhagic strokes associated with cerebral amyloid angiopathy poses a particular challenge in patients with indications for antithrombotic therapy and dictates a carefully individualized weighing of risks and benefits. Ongoing research is focused on tools to aid in risk prediction, early diagnostic markers, and identification of key pathogenic steps as targets for disease-modifying therapies.</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"394 18","pages":"1836-1845"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evidence-Based Approach to Covid-19 Vaccination. Reply.","authors":"Vinay Prasad, Martin A Makary","doi":"10.1056/NEJMc2507760","DOIUrl":"10.1056/NEJMc2507760","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"e37"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cerebral Amyloid Angiopathy.","authors":"Sihui Chen, Xueping Chen","doi":"10.1056/NEJMicm2511044","DOIUrl":"10.1056/NEJMicm2511044","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"1846"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147823570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Evidence-Based Approach to Covid-19 Vaccination.","authors":"Sabina Vohra-Miller, Elisabeth A Marnik","doi":"10.1056/NEJMc2507760","DOIUrl":"10.1056/NEJMc2507760","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":"e37"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144602261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Teaching Anatomy - To Dissect or Not to Dissect?","authors":"Katerina Lin, Sabine Hildebrandt, Paul McMenamin","doi":"10.1056/NEJMclde2518072","DOIUrl":"https://doi.org/10.1056/NEJMclde2518072","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"394 18","pages":"1862-1864"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing Bacterial Contamination of Blood Bags with a Double Knot.","authors":"Kathleen Selleng, Halima Ismail, Christian Kohler, Jan Wesche, Jessica Fuhrmann, Anne Kohler, Claudia Wiede, Vivien Huj, Yazid Ibrahim, Evgeny A Idelevich, Dalhat Gwarzo, Andreas Greinacher","doi":"10.1056/NEJMc2600589","DOIUrl":"https://doi.org/10.1056/NEJMc2600589","url":null,"abstract":"","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"394 18","pages":"1865-1866"},"PeriodicalIF":78.5,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147846226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}